Current Report Filing (8-k)
March 02 2021 - 8:19AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
__________________
FORM
8-K
__________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
March 2, 2021
__________________
EYENOVIA,
INC.
(Exact name of registrant as specified in
its charter)
__________________
Delaware
(State or other jurisdiction of incorporation)
001-38365
|
|
47-1178401
|
(Commission File Number)
|
|
(IRS Employer Identification No.)
|
295 Madison Avenue, Suite 2400, New York, New York 10017
|
(Address of principal executive offices) (Zip Code)
|
Registrant's telephone number, including
area code (917) 289-1117
__________________
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨
|
Written communications pursuant to Rule 425 under
the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d- 2(b))
|
|
¨
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e- 4(c))
|
Securities registered pursuant
to Section 12(b) of the Act:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common Stock, $0.0001 Par Value
|
EYEN
|
Nasdaq Capital Market
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this Chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this Chapter).
Emerging
growth company x
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
On March 2, 2021, Eyenovia, Inc. (the
“Company”) issued a press release announcing that the U. S. Food and Drug Administration has accepted the Company’s
New Drug Application for MydCombi™ and that the Company expects a Prescription Drug User Fee Act (“PDUFA”) date
in the fourth quarter of 2021.
Item 9.01.
|
Financial Statements and Exhibits.
|
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
EYENOVIA, INC.
|
|
|
|
Date: March 2, 2021
|
By:
|
/s/ John Gandolfo
Name: John Gandolfo
Title: Chief Financial
Officer
|
|
|
|
Eyenovia (NASDAQ:EYEN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Eyenovia (NASDAQ:EYEN)
Historical Stock Chart
From Sep 2023 to Sep 2024